July 2024/Market Relevance one minute read
anu bio-pharma has originated a first in class multi-functional biologic response modifier.
The ability to modulate the epithelium and endothelium structure/function, and immune cells uniquely expands the therapeutic landscape for several disease indications.
The market relevance of this biological response modifier is comparable to how the break through technology of anti-TNF alpha agents expanded the therapeutic landscape by attenuating inflammation. The various contributions to disease management substantiated the monetization of the anti-TNF alpha technology.
As a multi-target agent that limits cost intensive downstream events, practitioners and payors will recognize the distinct value of the multi-functional biological response modifier described herein: a strong payor focused value.
Accordingly, the contributions to disease management of this biological response modifier also substantiates the monetization of this novel immunomodulatory agent.
anu bio-pharma’s first in class technology maintains and fortifies the epithelial and endothelial structure/function. This is significant because the epithelium and endothelium function as full time gatekeepers and first responders to limit viral/bacterial pathogens, inflammation and disease progression.
A loss of epithelium – endothelium integrity contributes to direct and indirect untoward downstream cellular effects that predisposes and/or perpetuates chronic and critical medical conditions.
Currently, the medical community does not have a therapeutic to address diminished epithelial – endothelial integrity.
As such, this first in class, disease modifying biologic agent fills a treatment void. The pleiotropic properties of this treatment uniquely attenuates both disease precursors and clinical manifestations. These dual properties subsequently provide optimal, cost efficient patient care. This multi-functional, next generation therapeutic brings a substantial contribution to disease prevention/management.
In summary, anu bio-pharma’s biologic response modifier provides a new treatment paradigm to reduce vulnerability and/or limit disease progression. This disease modifying treatment has broad umbrella like properties that 1) fortifies the epithelia/endothelia barrier and 2) attenuates untoward downstream cell activity 3) while simultaneously potentiating endogenous homeostasis cell functions. In epithelia/endothelia speak these mechanisms are often referred to as fence and gate functions.
The navigation bar has a heading labeled Target Knowledge.
The section demonstrates the basic science for development of this innovative biologic response modifier. This information also substantiates the clinical impact this first in class biologic will provide to the medical management of several disease indications – conditions.
Noteworthy, throughout the drug development process the product label is the driver.
Also noteworthy, intellectual property protection is an inextricable component of drug and biologic product innovation.
In general, epithelial cells line pathways that come in contact with the outside environment: digestive/respiratory tracts. Whereas endothelial cells line internal pathways blood and lymphatic vessels that generally do not interact with the outside environment.
